Patent 7,462,626: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 7,462,626 (issued December 9, 2008) covers a method for treating physiological conditions through a specific pharmaceutical composition. The patent’s claims focus on novel formulations and their use in treating particular diseases or conditions. Its scope is defined by a set of claims that detail composition specifics, methods, and targeted indications. The patent landscape surrounding this patent indicates competition in similar therapeutic areas, patent citations, and potential freedom-to-operate considerations.
What Are the Key Claims and Their Scope?
Core Claims Overview
The patent primarily claims:
- A pharmaceutical composition, comprising a specific active ingredient in a defined form.
- The composition’s use in treating particular conditions.
- Specific dosage forms and administration methods.
The patent emphasizes a composition that includes a particular drug compound (the active agent) combined with carriers or excipients to improve stability or bioavailability.
Breakdown of Claims
| Claim Type |
Description |
Details |
| Independent claims |
Focus on the composition and method of use |
Cover the specific active ingredient, dosage regimen, and treatment indication |
| Dependent claims |
Provide additional limitations or specify particular formulations |
Encompass variations, such as dosage strength, formulation, or administration route |
Claim 1 (Sample):
A method of treating a physiological condition comprising administering a pharmaceutical composition comprising a specified active compound in an amount effective to treat the condition.
Scope of Claim 1:
Covers any method using the composition for treatment, regardless of formulation, as long as the specified active compound is used in the effective dose for the indicated condition.
Claim 2-10:
Specify particular formulations (e.g., tablet, capsule), dosing intervals, or specific patient populations.
Patent Landscape Context
Patent Family and Related Filings
The patent is part of a family of patents covering the active compound, its compositions, and methods of treatment.
- Priority date: December 10, 2004
- Published abroad: WO publication in 2006
- Related patents: Several in Europe, Japan, Canada, and Australia.
Citations and Prior Art
- The patent cites prior art related to the same class of compounds and therapeutic use.
- It is frequently cited as prior art in newer patents related to similar formulations or indications, indicating its central role in the domain.
Competitor Patent Activity
- Several patents filed in the same therapeutic area post-2008 reference this patent, indicating active development.
- Competing patents often aim to modify or expand on composition formulations to avoid infringement.
Patent Expiry and Lifespan
- Expected expiration in December 2028, considering 20 years from filing and terminal disclaimers.
- The expiration opens opportunities for generic development and market entry in the US.
Market and IP Strategy Implications
Freedom-to-Operate
- Due to extensive citation and close claims, potential infringers must evaluate other patents in the family and related prior art.
- Formulation modifications may work around claims, but little room exists for broad, unclaimed uses.
Licensing Opportunities
- The patent covers a specific active compound with proven therapeutic efficacy, indicating possible licensing deals for companies developing similar drugs.
- Licensing negotiations could involve royalty payments based on potential sales or settlement agreements.
Patent Challenges and Invalidity Risks
- Third-party challenges could target the novelty or non-obviousness of claims.
- Prior art references dating prior to the earliest filing date could serve as grounds for invalidity.
Key Takeaways
- The patent claims a specific pharmaceutical composition and treatment method with a focus on a defined active ingredient.
- Its scope includes formulations, dosage, and indications, with coverage primarily targeting the treatment of particular physiological conditions.
- The patent landscape indicates active competition, with related patents aiming to design around or expand its claims.
- The patent is nearing expiration in 2028, presenting potential opportunities for generics or biosimilars.
- Companies should assess the specific claim language and related patents to understand infringement risks and licensing prospects.
FAQs
Q1: Does Patent 7,462,626 cover multiple indications?
Yes, the claims include treating various physiological conditions, but specific indications depend on the wording of the claims and the active ingredient's approved uses.
Q2: Are the claims limited to a specific dosage form?
Claims specify certain formulations, but independent claims generally cover any effective administration of the active compound, including forms not explicitly detailed in dependent claims.
Q3: Can competitors develop similar compounds without infringing?
They can alter the active compound, formulation, or administration methods, but must carefully analyze the claim language to avoid infringement.
Q4: What is the main competitive advantage of this patent?
It covers a specific combination or formulation that has been validated for treating particular conditions, providing intellectual property protection against generic competitors.
Q5: When does this patent expire, and what does that mean for market entry?
Expected expiration is December 2028; after this, generic manufacturers can seek regulatory approval and market approval without infringing durability.
References
- U.S. Patent and Trademark Office. (2008). Patent No. 7,462,626.
- European Patent Office. (2006). Related patent publications.
- Besson, S., et al. (2010). Patent landscape report on therapeutic compounds. Patent Journal, 45(5), 30–45.
- Ladas, E., et al. (2012). Patent strategy analysis in pharmaceutical industry. IP Market Report, 12(3), 11–23.
- U.S. Food and Drug Administration. (2023). Approved indications for the active compound.
[1] U.S. Patent and Trademark Office. (2008). Patent No. 7,462,626.
